[{"id":"68b53629-bd68-4ac5-8c30-b43bdf31b541","acronym":"","url":"https://clinicaltrials.gov/study/NCT05552807","created_at":"2022-09-23T17:07:08.783Z","updated_at":"2024-07-02T16:36:03.566Z","phase":"Phase 1","brief_title":"SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT05552807","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • SCT200 • Anyouping (finotonlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/15/2022","start_date":" 06/15/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2022-09-23"},{"id":"b49f819c-3089-400b-a64f-32198fb43ffd","acronym":"SCT200-D101","url":"https://clinicaltrials.gov/study/NCT03808701","created_at":"2022-06-14T03:01:22.781Z","updated_at":"2024-07-02T16:37:03.731Z","phase":"Phase 1","brief_title":"Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03808701 - SCT200-D101","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCT200"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-01-17"},{"id":"7a27f60b-044a-4f80-ab02-778fc2ffe60c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03692689","created_at":"2021-01-18T18:05:54.721Z","updated_at":"2024-07-02T16:37:06.476Z","phase":"Phase 2","brief_title":"Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer","source_id_and_acronym":"NCT03692689","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCT200"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 07/20/2018","start_date":" 07/20/2018","primary_txt":" Primary completion: 09/30/2019","primary_completion_date":" 09/30/2019","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2018-10-02"},{"id":"cbdbff1d-60cf-4b40-bc6a-1d9ccfb23dae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03405272","created_at":"2021-01-18T16:48:07.688Z","updated_at":"2024-07-02T16:37:14.636Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC","source_id_and_acronym":"NCT03405272","lead_sponsor":"Sinocelltech Ltd.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCT200"],"overall_status":"Unknown status","enrollment":" Enrollment 110","initiation":"Initiation: 02/12/2018","start_date":" 02/12/2018","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2018-01-23"}]